Moderna in fill-finish agreement with Novocol Pharma for mRNA vaccines

• Moderna (NASDAQ:MRNA) and Ontario-based Novocol Pharma have signed an agreement for the latter to provide fill-finish, labelling and packaging of mRNA respiratory vaccines produced in Canada.
• The agreement will support Moderna's (MRNA) mRNA vaccine production operations in Laval, Quebec, which are expected to begin by the end of 2024.
• Moderna (MRNA) also received a grant from the Government of Ontario to support its production efforts.
• The biotech's respiratory syncytial virus (RSV) candidate, mRNA-1345, is in phase 3 of development.

More on Moderna

• Moderna to build mRNA vaccine manufacturing facility in Quebec

• Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19

• Moderna Is Great Value For Money Right Now